SEC begins asking Chinese companies for more VIE-related disclosures; SPC publishes model cases involving labor disputes as "996" crackdown continues; and CAC publishes draft rules for algorithm recommendation services
Ting Wu of Haiwen & Partners raises some questions to highlight how China's newly implemented drug patent linkage system attempts to resolve drug patent disputes in the early stages, which will have a sweeping impact on market entry strategies for chemical drugs in China
SEC to require Chinese issuers clarify VIE structures and whether listing has government backing; SPC issues judicial interpretation with restrictions on commercial applications of facial recognition technology; and MOFCOM unveils separate negative list for cross-border trade in services in Hainan
